Transforming Growth Factor-β Protects against Inflammation-Related Atherosclerosis in South African CKD Patients

Table 7

Relationship between TGF-β1 gene polymorphisms (T-869C and G-915C) and atherogenesis in CKD patients.

TGF-1 SNPs /Producer	Odds Ratio	95 Confidence Interval	P-value	Risk of Atherogenesis
T/T G/G (high)	1.26	0.53-3.01	0.406	No association
T/C G/G (high)	0.98	0.64-1.51	0.560	No association
T/C G/C (intermediate)	6.29	0.77-51.4	0.057	No association
C/C G/G (intermediate)	0.36	0.08-1.62	0.144	No association
T/T G/C (intermediate)	1.02	0.98-1.07	0.562	No association
C/C G/C (low)	0.31	0.04-2.69	0.259	No association
T/C C/C (low)	0.97	0.91-1.03	0.440	No association

TGFβ1: transforming growth factor β1. Odds ratios, 95% confidence interval, and p-value were derived from analyses of the strength of association between TGF-β1 gene polymorphisms and subclinical atherosclerosis in CKD patients with atherosclerosis compared to those without atherosclerosis (reference group).